The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride.
A generalized method was investigated for conversion of controlled-porosity osmotic pump release profiles from first-order to zero-order kinetics using diltiazem.HCl as a model drug. Diltiazem.HCl has an aqueous solubility greater than 590 mg/ml (37 degrees C) and was released from controlled-porosity osmotic pump devices with first-order kinetics. This high solubility was markedly reduced (155 mg/ml; 37 degrees C) in the presence of NaCl (1 M). Based on theory for osmotically actuated drug release, this reduced solubility would be expected to result in a zero-order release profile of greater than 80% of an initial diltiazem.HCl load. Devices were prepared with cores that contained diltiazem.HCl and sufficient NaCl granules coated with a microporous cellulose acetate butyrate 381-20 film to maintain a 1 M NaCl concentration within the drug compartment over a 16-hr period. This resulted in release of approximately 75% of the initial diltiazem.HCl load with zero-order kinetics over a 14- to 16-hr period. The in vivo performance of these devices in beagle dogs was analyzed. The in vivo percentage diltiazem absorbed profiles were superimposable with the in vitro release profile. These results suggest that diltiazem release and absorption from the solubility modulated osmotic pump occur throughout the GI tract in a fashion predictable from in vitro dissolution data.
McClelland
G A
GA
INTERx Research Corp., Merck Sharp & Dohme Research Laboratories, Lawrence, Kansas 66047.
Sutton
S C
SC
Engle
K
K
Zentner
G M
GM
D000818:Animals; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D004285:Dogs; D006863:Hydrogen-Ion Concentration; D015918:Infusion Pumps, Implantable; D012995:Solubility
D003692:Delayed-Action Preparations; D004110:Diltiazem